The Department of Health and Human Services is reportedly looking for comments from biosimilars stakeholders as part of the Trump administration’s to rein in drug costs.
A notice for comments was published on the Federal Register Wednesday, according to the Center for Biosimilars.
HHS is also pushing for the Food and Drug Administration to implement improvements on the Purple Book. The FDA uses the Purple Book to publish information on biological products.
Stakeholders have until July 16 to submit comments.